NCT00301834View on ClinicalTrials.gov

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Congenital Amegakaryocytic ThrombocytopeniaDiamond-blackfan AnemiaLeukemiaMyelodysplastic SyndromesSevere Congenital Neutropenia
Interventions
BIOLOGICAL

alemtuzumab

DRUG

busulfan

DRUG

cyclosporine

DRUG

fludarabine phosphate

DRUG

methotrexate

DRUG

methylprednisolone

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

peripheral blood stem cell transplantation

PROCEDURE

umbilical cord blood transplantation

Trial Locations (2)

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

53792-6164

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, San Francisco

OTHER

NCT00301834 - Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders | Biotech Hunter | Biotech Hunter